Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100VI6N
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥713m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥481m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.0bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax−¥1.2bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥2.2bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥35m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥4m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥271m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.9bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.062020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥28.53at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥21.66at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥36.7at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥77.99at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued39,505,200at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees47at 2024-12-31StandaloneNumber of employees
Employees51at 2023-12-31StandaloneNumber of employees
Employees49at 2022-12-31dStandaloneNumber of employees
Employees49at 2021-12-31dStandaloneNumber of employees
Employees42at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥2.5bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥527m
Drug Discovery And Developmentreportable segmentrevenue2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥814m
Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-12-31¥310m
—segment totalemployeesat 2024-12-3138 pure
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-12-31−¥504m
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥552m
Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-12-31¥682m
Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-12-31¥682m
Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-12-31¥399m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-12-31¥682m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-12-31¥682m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-12-31−¥653m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 835
ItemContextValueUnit
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember202952000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember577857000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember780809000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember780809000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-813784000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember309899000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-503885000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-526984000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1030869000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember2468857000JPY
AssetsCurrentYearInstant_NonConsolidatedMember2468857000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-03-28
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第21期（自　2024年１月１日　至　2024年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Company name in english cover pageFilingDateInstantChiome Bioscience Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　小池　正道
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number address of registered headquarter cover pageFilingDateInstant03-6383-3561
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number nearest place of contact cover pageFilingDateInstant03-6383-3561
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE26096
Fund codeFilingDateInstant－
Security codeFilingDateInstant45830
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Filer name in englishFilingDateInstantChiome Bioscience Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2024-01-01
Current period end dateFilingDateInstant2024-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2024-12-31

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass